JP2013522194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522194A5 JP2013522194A5 JP2012557033A JP2012557033A JP2013522194A5 JP 2013522194 A5 JP2013522194 A5 JP 2013522194A5 JP 2012557033 A JP2012557033 A JP 2012557033A JP 2012557033 A JP2012557033 A JP 2012557033A JP 2013522194 A5 JP2013522194 A5 JP 2013522194A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- item
- therapeutic agent
- dose
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 41
- 229940124597 therapeutic agent Drugs 0.000 claims description 41
- 239000000859 incretin Substances 0.000 claims description 22
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 108010011459 Exenatide Proteins 0.000 claims description 10
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 10
- 229960001519 exenatide Drugs 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000001771 impaired effect Effects 0.000 claims description 8
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 6
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 6
- 108010019598 Liraglutide Proteins 0.000 claims description 6
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 6
- 229960002701 liraglutide Drugs 0.000 claims description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 3
- -1 arubyglutide Chemical compound 0.000 claims description 3
- 230000000149 penetrating effect Effects 0.000 claims description 3
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 3
- 230000009747 swallowing Effects 0.000 claims description 3
- 108010048573 taspoglutide Proteins 0.000 claims description 3
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 claims description 3
- 229950007151 taspoglutide Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000000875 corresponding effect Effects 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 25
- 229940123208 Biguanide Drugs 0.000 description 7
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 5
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- 229960001319 parathyroid hormone Drugs 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 208000024799 Thyroid disease Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33994110P | 2010-03-10 | 2010-03-10 | |
| US61/339,941 | 2010-03-10 | ||
| PCT/US2010/062073 WO2011112229A2 (en) | 2010-03-10 | 2010-12-23 | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015127337A Division JP6118371B2 (ja) | 2010-03-10 | 2015-06-25 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522194A JP2013522194A (ja) | 2013-06-13 |
| JP2013522194A5 true JP2013522194A5 (https=) | 2014-02-20 |
| JP5931757B2 JP5931757B2 (ja) | 2016-06-08 |
Family
ID=44564048
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557033A Active JP5931757B2 (ja) | 2010-03-10 | 2010-12-23 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2015127337A Active JP6118371B2 (ja) | 2010-03-10 | 2015-06-25 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2017059281A Withdrawn JP2017105854A (ja) | 2010-03-10 | 2017-03-24 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2018145276A Pending JP2018165281A (ja) | 2010-03-10 | 2018-08-01 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015127337A Active JP6118371B2 (ja) | 2010-03-10 | 2015-06-25 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2017059281A Withdrawn JP2017105854A (ja) | 2010-03-10 | 2017-03-24 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2018145276A Pending JP2018165281A (ja) | 2010-03-10 | 2018-08-01 | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP2544668B1 (https=) |
| JP (4) | JP5931757B2 (https=) |
| CN (2) | CN105168174B (https=) |
| AU (3) | AU2010347732A1 (https=) |
| CA (1) | CA2792862C (https=) |
| WO (1) | WO2011112229A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8682440B2 (en) | 2009-08-03 | 2014-03-25 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| US8721620B2 (en) | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| CA2792862C (en) | 2010-03-10 | 2018-03-06 | Incube Labs, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| KR20200137035A (ko) * | 2012-01-06 | 2020-12-08 | 앤지 파마 유에스 엘엘씨 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| US20150057604A1 (en) * | 2012-04-05 | 2015-02-26 | Hisamitsu Pharmaceutical Co., Inc. | Puncture Device and Method for Manufacturing Same |
| US10264972B2 (en) | 2012-05-21 | 2019-04-23 | International Business Machines Corporation | Dispensing drugs from a companion diagnostic linked smart pill |
| HK1250011A1 (zh) | 2015-03-31 | 2018-11-23 | Sorriso Pharmaceuticals, Inc. | 具有蛋白酶可切割接头的肽构建体 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| US10220003B2 (en) * | 2016-03-09 | 2019-03-05 | Incube Labs, Llc | Methods and articles for delivering viable cells into solid tissue |
| JP7224917B2 (ja) | 2016-03-31 | 2023-02-20 | ソリッソ ファーマシューティカルズ，インク． | 組成物 |
| EP3547974B1 (en) * | 2016-12-02 | 2023-11-15 | Clexio Biosciences Ltd. | Gastric residence system |
| CN106725634B (zh) * | 2017-01-23 | 2024-01-16 | 天津医科大学总医院 | 肠道微生物采集胶囊 |
| WO2018213579A1 (en) * | 2017-05-17 | 2018-11-22 | Massachusetts Institute Of Technology | Self-actuating articles |
| US11103187B2 (en) * | 2017-06-12 | 2021-08-31 | Rani Therapeutics, Llc | Swallowable capsule, system and method for measuring gastric emptying parameters |
| CN107212846A (zh) * | 2017-08-07 | 2017-09-29 | 杨露 | 一种胃镜连接的胃酸检测装置 |
| WO2019071075A1 (en) * | 2017-10-06 | 2019-04-11 | Massachusetts Institute Of Technology | PIEZOELECTRIC DEVICES FOR GASTROINTESTINAL MOTILITY DETECTION |
| WO2019094521A1 (en) | 2017-11-07 | 2019-05-16 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
| CN108619611B (zh) * | 2018-05-04 | 2020-11-06 | 哈尔滨工业大学深圳研究生院 | 一种具有多方向施药功能的肠道微型胶囊机器人 |
| GB201900780D0 (en) * | 2019-01-21 | 2019-03-06 | Vibrant Ltd | Device and method for delivering a flowable ingestible medicament into the gastrointestinal tract of a user |
| EP4696361A3 (en) | 2019-02-01 | 2026-04-15 | Massachusetts Institute of Technology | Systems and methods for liquid injection |
| JP7420819B2 (ja) | 2019-02-01 | 2024-01-23 | ノボ・ノルデイスク・エー／エス | 作動機構を有する医療デバイス |
| US11833319B2 (en) * | 2019-03-01 | 2023-12-05 | Rani Therapeutics, Llc | Propulsive drug delivery from a swallowable device into a patients intestinal tract |
| KR102068616B1 (ko) * | 2019-03-15 | 2020-01-21 | (주)한국원자력 엔지니어링 | 장내 체류를 위한 내용물 운반체 |
| EP3962516B1 (en) * | 2019-05-03 | 2026-04-29 | Rani Therapeutics, LLC | Clotting factor viii preparations for delivery through tissue of the intestinal tract using a swallowable drug delivery device |
| CN113966242A (zh) * | 2019-06-07 | 2022-01-21 | 诺和诺德股份有限公司 | 具有递送构件脱离的可摄取装置 |
| WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
| JP7680377B2 (ja) | 2019-06-21 | 2025-05-20 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| CN114521124A (zh) * | 2019-08-26 | 2022-05-20 | Ajm Med-I-Caps有限公司 | 肠道诊断筛查装置及用于靶向胃肠道治疗的方法 |
| US11504519B2 (en) * | 2020-09-02 | 2022-11-22 | Fresenius Medical Care Holdings, Inc. | Releasable seal for catheter system |
| CN112717265B (zh) * | 2020-12-27 | 2023-04-07 | 河北医科大学第二医院 | 一种胃肠道肿瘤的靶点追踪装置及方法 |
| CN116897065B (zh) * | 2021-03-05 | 2025-10-14 | Bi生物技术有限公司 | 口服型物质传递装置 |
| CN113769249B (zh) * | 2021-09-10 | 2023-08-04 | 安翰科技(武汉)股份有限公司 | 一种给药胶囊 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| AU3957400A (en) | 1999-04-16 | 2000-11-02 | Novo Nordisk A/S | Dry, mouldable drug formulation |
| AU2004208580A1 (en) * | 2003-01-29 | 2004-08-12 | E-Pill Pharma Ltd. | Active drug delivery in the gastrointestinal tract |
| US20040267240A1 (en) * | 2003-01-29 | 2004-12-30 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
| US20050058701A1 (en) * | 2003-01-29 | 2005-03-17 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
| CN1953737A (zh) * | 2004-05-03 | 2007-04-25 | 埃-皮尔制药公司 | 胃肠道内的主动药物递送 |
| DE102004026615A1 (de) | 2004-06-01 | 2005-12-29 | Siemens Ag | Vorrichtung und Verfahren zur Freisetzung eines in das Körperinnere eines Patienten geführten therapeutischen Mittels |
| JP2008522778A (ja) * | 2004-12-14 | 2008-07-03 | イー−ピル ファーマ リミティド | 電気透過性増加を用いた薬物又は物質の局所輸送 |
| JP2008532568A (ja) * | 2005-01-18 | 2008-08-21 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 電子制御されるカプセル |
| AU2006273679B2 (en) * | 2005-07-26 | 2012-05-03 | Menachem P. Weiss | Extending intrabody capsule |
| US8021384B2 (en) * | 2005-07-26 | 2011-09-20 | Ram Weiss | Extending intrabody capsule |
| JP4402648B2 (ja) * | 2005-12-16 | 2010-01-20 | オリンパス株式会社 | 被検体内導入装置 |
| GB0603252D0 (en) * | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
| TR201902226T4 (tr) * | 2006-09-18 | 2019-03-21 | Vibrant Ltd | Gastrointestinal kapsül. |
| WO2009041525A1 (ja) * | 2007-09-26 | 2009-04-02 | Olympus Medical Systems Corp. | 被検体内導入システム |
| US8682440B2 (en) * | 2009-08-03 | 2014-03-25 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
| CA2785168C (en) * | 2009-12-24 | 2018-04-17 | Incube Labs, Llc | Swallowable drug delivery device and methods of drug delivery |
| CA2792862C (en) * | 2010-03-10 | 2018-03-06 | Incube Labs, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
-
2010
- 2010-12-23 CA CA2792862A patent/CA2792862C/en active Active
- 2010-12-23 JP JP2012557033A patent/JP5931757B2/ja active Active
- 2010-12-23 WO PCT/US2010/062073 patent/WO2011112229A2/en not_active Ceased
- 2010-12-23 EP EP10847622.7A patent/EP2544668B1/en not_active Revoked
- 2010-12-23 EP EP19177552.7A patent/EP3603624A1/en not_active Withdrawn
- 2010-12-23 CN CN201510345861.8A patent/CN105168174B/zh active Active
- 2010-12-23 AU AU2010347732A patent/AU2010347732A1/en not_active Abandoned
- 2010-12-23 CN CN201080066694.9A patent/CN103025319B/zh active Active
-
2015
- 2015-06-25 JP JP2015127337A patent/JP6118371B2/ja active Active
-
2016
- 2016-10-28 AU AU2016250444A patent/AU2016250444B2/en active Active
-
2017
- 2017-03-24 JP JP2017059281A patent/JP2017105854A/ja not_active Withdrawn
-
2018
- 2018-08-01 JP JP2018145276A patent/JP2018165281A/ja active Pending
-
2019
- 2019-03-13 AU AU2019201724A patent/AU2019201724B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522194A5 (https=) | ||
| US10596359B2 (en) | Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device | |
| JP2020058871A5 (https=) | ||
| AU2019201724B2 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
| FI3756657T3 (fi) | Nieltävä lääkkeenantolaite | |
| RU2547990C2 (ru) | Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства | |
| JP2008520544A5 (ja) | 癌関連疲労の治療または予防のための医薬の製造への使用方法 | |
| JP2013515576A5 (https=) | ||
| JP2018519313A5 (https=) | ||
| KR101900520B1 (ko) | 복합 조성물 | |
| JP2019517542A5 (https=) | ||
| IL307966A (en) | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug | |
| JP2014524480A5 (https=) | ||
| WO2004002445A3 (en) | Novel floating dosage form | |
| JP2002544231A5 (https=) | ||
| JP2004530721A5 (https=) | ||
| WO2011041311A2 (en) | Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods | |
| EP4661842A2 (en) | Programmable drug-device microneedle system for the treament of diabetes, obesity, and associated conditions | |
| EP4090351B1 (en) | Dosing regimen of glp-1 | |
| KR20250117456A (ko) | 소분자 항바이러스제의 고체 투여 형태 및 그의 용도 | |
| Croasdell | European Association for the Study of Diabetes (EASD)-53rd Annual Meeting. Lisbon, Portugal-September 11-15, 2017 | |
| HK1245156A1 (en) | Rapid establishment and/or termination of substantial steady-state drug delivery |